Cover Image
市場調查報告書

結核 (TB) 的預測:主要11市場

Tuberculosis Forecast In 11 Major Markets 2015 -2025

出版商 Black Swan Analysis 商品編碼 342579
出版日期 內容資訊 英文 51 Pages
訂單完成後即時交付
價格
Back to Top
結核 (TB) 的預測:主要11市場 Tuberculosis Forecast In 11 Major Markets 2015 -2025
出版日期: 2015年10月27日 內容資訊: 英文 51 Pages
簡介

結核 (TB) 是慢性的細菌感染疾病,由於人類結核菌的變異引起。初期的感染部位是肺,不過,也有影響肺之外部位的情況。由於結核 (TB) 感染者的咳嗽和噴嚏等,透過飛沫的空氣傳播感染傳染。

本報告提供主要11個市場 (美國、法國、德國、義大利、西班牙、英國、巴西、日本、印度、波蘭、羅馬尼亞) 的結核 (TB) 的依照目前患者數 (性別、年齡世代) 調查分析、目前盛行率,加上疾病概要、危險因素、疾病診斷預後、主要的症狀和併發症等系統性資訊。

圖表

簡介

病因

危險因素和預防

疾病診斷

變異:地區/各民族

疾病預後與臨床過程

疾病相關的主要併發症/特徵

定量化患者數的手法

結核 (TB) 的盛行率top line

結核 (TB) 的特徵

  • 分類
  • 地方
  • 成為原因的種
  • 患者的來源

結核 (TB) 的案例類型

  • 治療成績

結核 (TB) 的相關症狀

  • HIV
  • 結核藥物抗性

簡稱

相關出版

以線上的患者為基礎的資料庫

以患者為基礎的產品

線上的價格資料和平台

參考文件

附錄

目錄
Product Code: TUBE0011015

Tuberculosis (TB) is a chronic bacterial infection caused by variants of Mycobacterium tuberculosis. Usually affecting the lungs as the primary site of infection, but can affect extra-pulmonary sites also. Transmission occurs by an infected person with active TB, coughing, sneezing or even talking to other people. Droplets of saliva or mucus enter the air and other people are able to inhale the mycobacterium within the droplets.

This report provides the current incidence population for TB across 11 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, India, Poland and Romania) split by gender and 5-year age cohort. Along with the current incidence, the report provides an overview of TB patient origin status, drug resistance and causative species of TB. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of TB have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for TB include:

  • HIV/AIDS
  • Diabetes
  • Bloody sputum
  • Bone pain

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global TB's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of TB and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on TB's prevalent population.
  • Examination of the incidence of the different causative species for TB.
  • Identify sub-populations within TB which require treatment.
  • Gain an understanding of the specific markets that have the largest number of TB patients.

Coverage

  • U.S.
  • United Kingdom
  • France
  • Germany
  • Italy
  • Spain
  • Japan
  • U.K.
  • India
  • Poland
  • Romania

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key Co-morbid Conditions/ Features Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Incidence for Tuberculosis
  • Features of Tuberculosis
    • Classification of Tuberculosis
    • Tuberculosis Location
    • Tuberculosis-Causing Species
    • Origin Status of Patients with Tuberculosis
  • Tuberculosis Case Type
    • Treatment Outcome of Tuberculosis Case Type
  • Associated Conditions of Tuberculosis
    • HIV
    • Tuberculosis Drug Resistance
  • Abbreviations used in the Report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Tables

  • 1. Incidence of Tuberculosis, total (000s)
  • 2. Incidence of Tuberculosis, males (000s)
  • 3. Incidence of Tuberculosis, females (000s)
  • 4. Diagnosis classification of Tuberculosis, total (000s)
  • 5. Site affected by Tuberculosis, total (000s)
  • 6. Mycobacterium species causing Tuberculosis, total (000s)
  • 7. Origin status of patients with Tuberculosis, total (000s)
  • 8. Case type of patients with Tuberculosis, total (000s)
  • 9. Treatment outcome of new cases of Tuberculosis, total (000s)
  • 10. Treatment outcome of previously treated cases of Tuberculosis, total (000s)
  • 11. HIV in patients with Tuberculosis, total (000s)
  • 12. Miliary Tuberculosis in Tuberculosis patients with HIV, total (000s)
  • 13. Multi-drug resistance in patients with Tuberculosis, total (000s)
  • 14. Any Tuberculosis drug resistance in patients with Tuberculosis, total (000s)
  • 15. Isoniazid resistance in patients with Tuberculosis, total (000s)
  • 16. Abbreviations and Acronyms used in the report
  • 17. USA Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 18. USA Incidence of Tuberculosis by 5-yr age cohort, females (000s)
  • 19. France Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 20. France Incidence of Tuberculosis by 5-yr age cohort, females (000s)
  • 21. Germany Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 22. Germany Incidence of Tuberculosis by 5-yr age cohort, females (000s)
  • 23. Italy Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 24. Italy Incidence of Tuberculosis by 5-yr age cohort, females (000s)
  • 25. Spain Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 26. Spain Incidence of Tuberculosis by 5-yr age cohort, females (000s)
  • 27. United Kingdom Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 28. United Kingdom Incidence of Tuberculosis by 5-yr age cohort, females (000s)
  • 29. Brazil Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 30. Brazil Incidence of Tuberculosis by 5-yr age cohort, females (000s)
  • 31. Japan Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 32. Japan Incidence of Tuberculosis by 5-yr age cohort, females (000s)
  • 33. India Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 34. India Incidence of Tuberculosis by 5-yr age cohort, females (000s)
  • 35. Poland Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 36. Poland Incidence of Tuberculosis by 5-yr age cohort, females (000s)
  • 37. Romania Incidence of Tuberculosis by 5-yr age cohort, males (000s)
  • 38. Romania Incidence of Tuberculosis by 5-yr age cohort, females (000s)
Back to Top